Maron Bradley A
Brigham and Women's Hospital and Harvard Medical School, Department of Medicine, Division of Cardiovascular Medicine, 75 Francis St, Boston, and the Department of Cardiology, Veterans Affairs Boston Healthcare System, West Roxbury, Massachusetts, USA.
Can J Cardiol. 2015 Apr;31(4):515-20. doi: 10.1016/j.cjca.2014.09.021. Epub 2014 Sep 28.
Pulmonary arterial hypertension (PAH) is a highly morbid cardiopulmonary disease characterized by plexogenic pulmonary arteriole remodelling. Importantly, PAH severity correlates inversely with cardiac output and directly with pulmonary vascular resistance and right atrial pressure, illustrating the importance of accurately measured hemodynamics to define the clinical profile of patients. Currently available noninvasive technology offers only hemodynamic estimates. In contrast, right heart catheterization is the principle diagnostic procedure in PAH and is required to: (1) definitively exclude alternative pulmonary vascular diseases; and (2) quantify hemodynamics at baseline, after vasoreactivity testing, or in response to therapy to prognosticate outcome and guide therapeutic escalation.
肺动脉高压(PAH)是一种高发病率的心肺疾病,其特征为丛状肺小动脉重塑。重要的是,PAH的严重程度与心输出量呈负相关,与肺血管阻力和右心房压力呈正相关,这表明准确测量血流动力学对于确定患者的临床特征至关重要。目前可用的非侵入性技术仅提供血流动力学估计值。相比之下,右心导管检查是PAH的主要诊断方法,并且需要用于:(1)明确排除其他肺血管疾病;(2)在基线、血管反应性测试后或对治疗的反应中量化血流动力学,以预测预后并指导治疗升级。